Technology
Health
Biotechnology

Palatin Technologies

$0.9789
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0194 (-1.94%) As of 12:58 PM EDT today
-$0.0194 (-1.94%) Today

Why Robinhood?

You can buy or sell PTN and other stocks, options, ETFs, and crypto commission-free!

About PTN

Palatin Technologies, Inc., also called Palatin Technologies, is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). Read More The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Employees
19
Headquarters
Cranbury, New Jersey
Founded
1986
Market Cap
202.72M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.20M
High Today
$1.00
Low Today
$0.97
Open Price
$0.98
Volume
540.71K
52 Week High
$1.78
52 Week Low
$0.59

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
US
North America

PTN Earnings

-$0.04
-$0.01
$0.03
$0.06
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Expected Sep 12, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.